Q-omics provides the consensus-scored NCR3 profile across patient tissues and cancer cell-line models. NCR3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NCR3 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, NCR3 RNA expression shows 17,147 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where NCR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCR3 survival associations across molecular data types. NCR3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCR3 RNA expression–survival associations across cancer types. High NCR3 expression shows unfavorable associations in LAML and KIRP, but favorable associations in HNSC, SKCM, UCEC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NCR3 RNA expression.
This table summarizes NCR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NCR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCR3 shows lower tumor expression in COAD, LUSC, LUAD and BLCA and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher NCR3 RNA expression in tumor versus normal tissue (log2 FC = +1.172, t-test p < 0.001).
This table shows molecular features associated with NCR3 in patient tissues and cancer cell lines. In patient samples, NCR3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NCR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
